JNCE Jounce Therapeutics Inc

Price (delayed)

$7.27

Market cap

$372.28M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.04

Enterprise value

$192.16M

Highlights
The company's quick ratio has surged by 94% YoY and by 86% QoQ
The equity has soared by 83% YoY and by 32% from the previous quarter
The EPS has plunged by 179% YoY but it has increased by 16% from the previous quarter
JNCE's gross profit has plunged by 53% YoY but it is up by 2.5% from the previous quarter

Key stats

What are the main financial stats of JNCE
Market
Shares outstanding
51.21M
Market cap
$372.28M
Enterprise value
$192.16M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.18
Price to sales (P/S)
5.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.01
Earnings
Revenue
$63.88M
EBIT
-$43.93M
EBITDA
-$40.68M
Free cash flow
-$38M
Per share
EPS
-$1.04
Free cash flow per share
-$0.83
Book value per share
$6.16
Revenue per share
$1.39
TBVPS
$6.64
Balance sheet
Total assets
$305.15M
Total liabilities
$25.7M
Debt
$16.15M
Equity
$279.45M
Working capital
$254.09M
Liquidity
Debt to equity
0.06
Current ratio
20.66
Quick ratio
19.92
Net debt/EBITDA
4.43
Margins
EBITDA margin
-63.7%
Gross margin
100%
Net margin
-68.8%
Operating margin
-69.7%
Efficiency
Return on assets
-20.8%
Return on equity
-24.3%
Return on invested capital
-48.4%
Return on capital employed
-15%
Return on sales
-68.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

JNCE stock price

How has the Jounce Therapeutics stock price performed over time
Intraday
-2.55%
1 week
2.83%
1 month
-7.15%
1 year
18.6%
YTD
3.86%
QTD
-29.21%

Financial performance

How have Jounce Therapeutics's revenue and profit performed over time
Revenue
$63.88M
Gross profit
$63.88M
Operating income
-$44.52M
Net income
-$43.93M
Gross margin
100%
Net margin
-68.8%
JNCE's gross profit has plunged by 53% YoY but it is up by 2.5% from the previous quarter
Jounce Therapeutics's revenue has plunged by 53% YoY but it has increased by 2.5% from the previous quarter
JNCE's operating margin is up by 3.7% QoQ
Jounce Therapeutics's net margin has increased by 2.1% from the previous quarter

Growth

What is Jounce Therapeutics's growth rate over time

Valuation

What is Jounce Therapeutics stock price valuation
P/E
N/A
P/B
1.18
P/S
5.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.01
The EPS has plunged by 179% YoY but it has increased by 16% from the previous quarter
The equity has soared by 83% YoY and by 32% from the previous quarter
The stock's price to book (P/B) is 49% less than its 5-year quarterly average of 2.3 and 38% less than its last 4 quarters average of 1.9
Jounce Therapeutics's revenue has plunged by 53% YoY but it has increased by 2.5% from the previous quarter
JNCE's price to sales (P/S) is 19% higher than its 5-year quarterly average of 4.4

Efficiency

How efficient is Jounce Therapeutics business performance
JNCE's return on assets has dropped by 198% year-on-year but it is up by 14% since the previous quarter
Jounce Therapeutics's return on equity has shrunk by 186% YoY but it has increased by 17% QoQ
The ROS has increased by 2.1% from the previous quarter

Dividends

What is JNCE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for JNCE.

Financial health

How did Jounce Therapeutics financials performed over time
The current ratio has surged by 94% year-on-year and by 89% since the previous quarter
The company's quick ratio has surged by 94% YoY and by 86% QoQ
Jounce Therapeutics's debt is 94% less than its equity
The equity has soared by 83% YoY and by 32% from the previous quarter
The company's debt to equity has shrunk by 54% YoY and by 25% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.